Substituted bicyclic compounds
US-9522888-B2 · Dec 20, 2016 · US
Antioxidant compound having anti atherosclerotic effect and preparation thereof
US9580452B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9580452-B2 |
| Application number | US-201615047872-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2016 |
| Priority date | Feb 19, 2015 |
| Publication date | Feb 28, 2017 |
| Grant date | Feb 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of TPP+ coupled esculetin (mitochondria-targeted esculetin [Mito-Esc]) followed by the biological evaluation of Mito-Esc for its ability to attenuate Angiotensin-II-induced atherosclerosis in apolipoproteinE knockout (ApoE −/−) mice along with the endothelial cell age-delaying effects of Mito-Esc.
First claim
Opening claim text (preview).
We claim: 1. An antioxidant compound having the general formula 1: wherein X=is a C 1 to C 30 carbon chain; Z=any halogen; and R=H. 2. A compound as claimed in claim 1 wherein the anion Z − is bromide. 3. A compound as claimed in claim 1 , wherein X optionally includes one or more double or triple bonds. 4. A compound as claimed in claim 3 , wherein R is octylene. 5. A method for ameliorating oxidative stress or cell death that is induced by H 2 O 2 or angiotensin-II in human aortic endothelial cells (HAEC), comprising contacting the cells with a compound as claimed in claim 1 . 6. A method for treating Angiotensin-II-induced atherosclerosis in a human patient suffering therefrom, comprising administering to the patient a compound as claimed in claim 1 .
Assignees
Inventors
Classifications
- C07F9/65522Primary
condensed with carbocyclic rings or carbocyclic ring systems · CPC title
Dyes containing an onium group attached to the dye skeleton via a bridge · CPC title
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
Coumarine dyes · CPC title
Phosphorus compounds · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9580452B2 cover?
- The present invention relates to an antioxidant compound having anti atherosclerotic effect and preparation thereof. The present invention more particularly relates to the synthesis of TPP+ coupled esculetin (mitochondria-targeted esculetin [Mito-Esc]) followed by the biological evaluation of Mito-Esc for its ability to attenuate Angiotensin-II-induced atherosclerosis in apolipoproteinE knockou…
- Who is the assignee on this patent?
- Council Scient Ind Res
- What technology area does this patent fall under?
- Primary CPC classification C07F9/65522. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).